Clinical trial
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
NCT05595499
Study timeline
Study start (actual)2023-03-27Date precision: day
Registry last updated2026-07-17
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Anatomic Stage I Breast Cancer AJCC v8unresolved
Anatomic Stage II Breast Cancer AJCC v8unresolved
Anatomic Stage III Breast Cancer AJCC v8unresolved
Interventions
Biospecimen CollectionPROCEDURE
FisetinDRUG
Sponsors & collaborators
Jonsson Comprehensive Cancer Centerlead sponsor
National Cancer Institute (NCI)collaborator
National Institute on Aging (NIA)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05595499 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.